NCT07748351Active, not recruitingPhase 1
A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)
A Study to Evaluate the Relative Bioavailability of Multiple Formulations of MK-4082 in Overweight/Obese Participants
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) and formulation (version) of the study medicine that can be used in future studies. The goals of this study are to learn about: The safety of different formulations of MK-4082 and if people tolerate them What happens to different formulations of MK-4082 in a person's body over time
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 31 Jul 2026
- Start date
- 25 Aug 2026
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Obesity
- NCT number
- NCT07748351
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 48
- From 25 Aug 2026 to the primary completion date, 15 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has a history of previous surgical treatment for obesity that may induce malabsorption, history of bowel resection \>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss
Other illness
- Has an individual or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 2
Other
- The main exclusion criteria include but are not limited to the following:
Who the study is looking for
- The main inclusion criteria include but are not limited to the following:
- Is in good health
- Has a body mass index (BMI) between 25 and 40 kg/m\^2, inclusive and weighs at least 60 kg
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ProSciento Inc. ( Site 0002) Coordinator of this site? Confirm its status | Chula Vista | United States | Unknown status |
| ICON Early Phase Services ( Site 0003) Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.